{
    "id": 30547,
    "fullName": "EGFR N771_P772insH",
    "impact": "insertion",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "EGFR N771_P772insH results in the insertion of a histidine (H) in the protein kinase domain of the Egfr protein between amino acids 771 and 772 (UniProt.org). N771_P772insH has not been biochemically characterized, but is predicted to result in a gain of function based on the effect of other Egfr exon 20 insertions (PMID: 16187797).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 410,
                    "pubMedId": 16187797,
                    "title": "Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16187797"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "N771_P772insH",
    "createDate": "07/22/2019",
    "updateDate": "07/22/2019",
    "referenceTranscriptCoordinates": {
        "id": 181232,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55181323_55181324insATC",
        "cDna": "c.2314_2315insATC",
        "protein": "p.N771_P772insH",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19397,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Poziotinib (HM781-36B) inhibited Egfr phosphorylation and cell viability, and induced apoptosis in a lung cancer patient cell line harboring EGFR N771_P772insH in culture (PMID: 31467113).",
            "molecularProfile": {
                "id": 32755,
                "profileName": "EGFR N771_P772insH"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16160,
                    "pubMedId": 31467113,
                    "title": "TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31467113"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19396,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAS6417 inhibited Egfr phosphorylation and cell viability, and induced apoptosis in a lung cancer patient cell line harboring EGFR N771_P772insH in culture (PMID: 31467113).",
            "molecularProfile": {
                "id": 32755,
                "profileName": "EGFR N771_P772insH"
            },
            "therapy": {
                "id": 6994,
                "therapyName": "CLN-081",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16160,
                    "pubMedId": 31467113,
                    "title": "TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31467113"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 32755,
            "profileName": "EGFR N771_P772insH",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 181232,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55181323_55181324insATC",
            "cDna": "c.2314_2315insATC",
            "protein": "p.N771_P772insH",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}